{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:25:34Z","timestamp":1790526334060,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":3931,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Millennium Pharmaceuticals, Inc.;"},{"name":"Johnson & Johnson Pharmaceutical Research & Development L.L.C"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1093\/annonc\/mdn656","type":"journal-article","created":{"date-parts":[[2008,12,13]],"date-time":"2008-12-13T03:18:50Z","timestamp":1229138330000},"page":"520-525","source":"Crossref","is-referenced-by-count":292,"title":["Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study"],"prefix":"10.1016","volume":"20","author":[{"given":"A.","family":"Goy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Djulbegovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Epner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.A.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Boral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.I.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdn656_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.cco.0000174039.69656.2b","article-title":"Biology and therapy of mantle cell lymphoma","volume":"17","author":"Williams","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hon.767","article-title":"Update on the molecular biology of mantle cell lymphoma","volume":"24","author":"Bertoni","year":"2006","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-003-0774-2","article-title":"Mantle cell lymphoma: established therapeutic options and future directions","volume":"83","author":"Lenz","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdn656_bb0025","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0030","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn656_bb0035","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdn656_bb0040","first-page":"1580","article-title":"High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma","volume":"90","author":"Vigouroux","year":"2005","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdn656_bb0045","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0050","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0055","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0060","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdn656_bb0065","first-page":"v66","article-title":"Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: results of a multicenter phase II experience","volume":"16","author":"O'Connor","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0070","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0075","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0080","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0085","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0090","unstructured":"National Cancer InstituteNational Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events Accessed 1 May 2008 http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf"},{"key":"10.1093\/annonc\/mdn656_bb0095","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn656_bb0100","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdn656_bb0105","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","article-title":"Update of the M.D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas","volume":"8","author":"Fayad","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdn656_bb0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2141.2007.06908.x","article-title":"A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma","volume":"140","author":"Evens","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdn656_bb0115","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0120","first-page":"111a","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial","volume":"106","author":"San Miguel","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn656_bb0125","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn656_bb0130","doi-asserted-by":"crossref","first-page":"758a","DOI":"10.1182\/blood.V110.11.2573.2573","article-title":"Immunohistochemical analyses for potential biomarkers of bortezomib activity in mantle cell lymphoma from the PINNACLE phase 2 trial","volume":"110","author":"Goy","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn656_bb0135","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V110.11.1294.1294","article-title":"Pre-treatment p27 and Bcl-6 staining levels correlate with response to bortezomib in non-Hodgkin lymphoma: results from a tissue microarray analysis","volume":"110","author":"Gerecitano","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn656_bb0140","doi-asserted-by":"crossref","first-page":"693a","DOI":"10.1182\/blood.V108.11.2449.2449","article-title":"High dose cytarabine salvage regimen combined with bortezomib is feasible and highly effective in relapsed mantle cell lymphoma","volume":"108","author":"Weigert","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn656_bb0145","first-page":"435","article-title":"Bortezomib, rituximab, and dexamethason (BORID) induces high response rates and durable complete remissions in patients with relapsed\/refractory mantle cell lymphoma","volume":"92","author":"Drach","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdn656_bb0150","doi-asserted-by":"crossref","first-page":"147a","DOI":"10.1182\/blood.V106.11.491.491","article-title":"Phase I\/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results","volume":"106","author":"Leonard","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn656_bb0155","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/jco.2007.25.18_suppl.8010","article-title":"Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: a randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"25","author":"Mounier","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0160","doi-asserted-by":"crossref","first-page":"456s","DOI":"10.1200\/jco.2007.25.18_suppl.8062","article-title":"A feasibility study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma","volume":"25","author":"Kahl","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn656_bb0165","doi-asserted-by":"crossref","first-page":"266b","DOI":"10.1182\/blood.V106.11.4744.4744","article-title":"Potent single agent activity and tumor selectivity of bortezomib in mantle cell lymphoma: first impressions from a randomized phase II study of EPOCH-rituximab-bortezomib in untreated mantle cell lymphoma","volume":"106","author":"Wiestner","year":"2005","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419413914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419413914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/20\/3\/520\/457856\/mdn656.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T18:53:10Z","timestamp":1589395990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419413914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0923753419413914"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn656","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}